Histiocytosis Treatment Market is expected to rise from USD 51.80 Billion in 2025 to USD 122.63 Billion by 2036, growing at a CAGR of 9.0%. Langerhans cell histiocytosis type will dominate with a 46.3% type share, while Emapalumab will lead the drugs segment with a 38.7% share.